Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;29(5):524-538.
doi: 10.1037/pha0000510. Epub 2021 Jul 5.

Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review

Tessa Nalven  1 , Nichea S Spillane  1 , Melissa R Schick  1 , Lisa L Weyandt  1
Affiliations

Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review

Tessa Nalven et al. Exp Clin Psychopharmacol. 2021 Oct.

Abstract

Pharmacological treatments for opioid use disorders (OUDs) may have mixed efficacy across diverse groups, i.e., sex/gender, race/ethnicity, and socioeconomic status (SES). The present systematic review aims to examine how diverse groups have been included in U.S. randomized clinical trials examining pharmacological treatments (i.e., methadone, buprenorphine, or naltrexone) for OUDs. PubMed was systematically searched according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The initial search yielded 567 articles. After exclusion of ineligible articles, 50 remained for the present review. Of the included articles, 14.0% (n = 7) reported both full (i.e., accounting for all participants) sex/gender and race/ethnicity information; only two of those articles also included information about any SES indicators. Moreover, only 22.0% (n = 11) reported full sex/gender information, and 42.0% (n = 21) reported full racial/ethnic information. Furthermore, only 10.0% (n = 5) reported that their lack of subgroup analyses or diverse samples was a limitation to their studies. Particularly underrepresented were American Indian/Alaska Native (AI/AN), Asian, Native Hawaiian/Other Pacific Islander (NH/OPI), and multiracial individuals. These results also varied by medication type; Black individuals were underrepresented in buprenorphine randomized controlled trials (RCTs) but were well represented in RCTs for methadone and/or naltrexone. In conclusion, it is critical that all people receive efficacious pharmacological care for OUDs given the ongoing opioid epidemic. Findings from the present review, however, support that participants from diverse or marginalized backgrounds are underrepresented in treatment trials, despite being at increased risk for disparities related to OUDs. Suggestions for future research are advanced. (PsycInfo Database Record (c) 2021 APA, all rights reserved).

PubMed Disclaimer

Conflict of interest statement

Declaration of Interest: The authors report no conflict of interest.

Figures

Figure 1
Figure 1
Flow Diagram for PRISMA Systematic Review Procedure
See this image and copyright information in PMC

References

    1. American Psychiatric Association (APA). (2013). Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub.
    1. American Psychiatric Association (APA). (2018). Opioid use disorder. https://www.psychiatry.org/patients-families/addiction/opioid-use-disord...
    1. Anderson KO, Green CR, & Payne R (2009). Racial and ethnic disparities in pain: causes and consequences of unequal care. The Journal of Pain, 10(12), 1187–1204. - PubMed
    1. Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, Hillhouse M, Brady KT, & Ling W (2011). Comparative profiles of men and women with opioid dependence: Results from a national multisite effectiveness trial. American Journal of Drug and Alcohol Abuse, 37(5), 313–323. 10.3109/00952990.2011.596982 - DOI - PMC - PubMed
    1. Barbosa-Leiker C, McPherson S, Layton ME, Burduli E, Roll JM, & Ling W (2018). Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment. American Journal of Drug and Alcohol Abuse, 44(4), 488–496. 10.1080/00952990.2018.1458234 - DOI - PMC - PubMed

Publication types

MeSH terms